

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

NALM-6

RRID:CVCL_0092

Type: Cell Line

Proper Citation

RRID:CVCL_0092

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0092

Proper Citation: RRID:CVCL_0092

Description: Cell line NALM-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult B acute lymphoblastic leukemia

Defining Citation: [PMID:83966](#), [PMID:155647](#), [PMID:2140233](#), [PMID:2415623](#), [PMID:2783384](#), [PMID:2939141](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:8847894](#), [PMID:9067587](#), [PMID:9510473](#), [PMID:9680106](#), [PMID:9738977](#), [PMID:10490826](#), [PMID:10695022](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:11416159](#), [PMID:11986953](#), [PMID:15843827](#), [PMID:16405397](#), [PMID:16408098](#), [PMID:16969076](#), [PMID:20103924](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20575032](#), [PMID:20922763](#), [PMID:22460905](#), [PMID:23596518](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29786757](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31243274](#), [PMID:31305009](#), [PMID:31978347](#), [PMID:34823530](#), [PMID:35124168](#), [PMID:35354797](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NALM-6

Synonyms: Nalm-6, NALM 6, Nalm 6, NALM6, Nalm6, NALM-6-M1

Cross References: BTO:BTO_0003288, CLO:CLO_0007938, CLO:CLO_0050970, EFO:EFO_0002245, CLDB:cl3631, CLDB:cl3632, AddexBio:C0003030/5015, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:273, BioSample:SAMN03472035, BioSample:SAMN03473163, BioSample:SAMN03473413, BioSample:SAMN10988491, cancercellines:CVCL_0092, Cell_Model_Passport:SIDM00429, ChEMBL-Cells:ChEMBL3307559, ChEMBL-Targets:ChEMBL614187, CLS:300297, Cosmic:801722, Cosmic:850385, Cosmic:889112, Cosmic:908158, Cosmic:919147, Cosmic:991553, Cosmic:998708, Cosmic:999748, Cosmic:1012106, Cosmic:1037711, Cosmic:1070706, Cosmic:1093787, Cosmic:1130246, Cosmic:1191699, Cosmic:1483361, Cosmic:1509198, Cosmic:1524810, Cosmic:2491082, Cosmic:2649232, Cosmic-CLP:908158, DepMap:ACH-000938, DSMZ:ACC-128, DSMZCellDive:ACC-128, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10534-107G3, GDSC:908158, GEO:GSM236797, GEO:GSM236833, GEO:GSM887347, GEO:GSM888423, GEO:GSM1670142, GEO:GSM5137734, IARC_TP53:21527, IGRhCellID:NALM6, LiGeA:CCLE_665, LINCS_LDP:LCL-1007, Lonza:812, NCBI_Iran:C212, PharmacDB:NALM6_980_2019, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL_0092, PubChem_Cell_line:CVCL_0092, RCB:RCB1933, TKG:TKG 0413, Wikidata:Q54907426

ID: CVCL_0092

Record Creation Time: 20220427T220832+0000

Record Last Update: 20260920T004601+0000

Ratings and Alerts

No rating or validation information has been found for NALM-6.

No alerts have been found for NALM-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 531 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. Molecular cancer therapeutics, 25(5), 727.

Yoshida Y, et al. (2026) PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters. *Communications biology*, 9(1), 135.

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. *Cell reports. Medicine*, 7(5), 102782.

Saville JR, et al. (2026) Exploring the Role of Environmental Factors on Chromosomal Translocations Associated With Childhood Leukaemia. *Cancer medicine*, 15(3), e71713.

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. *Cancer immunology research*, 14(8), 1292.

Garcia C, et al. (2026) FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. *Leukemia*, 40(8), 1763.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Liu S, et al. (2026) γ -hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. *Cell*, 189(6), 1701.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. *Cancer discovery*.

Zhang H, et al. (2026) Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-cell Efficacy and Lowers Systemic Toxicity. *Cancer immunology research*, 14(5), 845.

Awasthi BP, et al. (2026) Disruption of Cytoskeleton Induces Physiologically and Morphologically Dysfunctional Mitochondria in B-ALL Cells. *Cell biochemistry and function*, 44(3), e70190.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. *bioRxiv : the preprint server for biology*.

Saito S, et al. (2026) Human APOBEC3G suppresses homologous recombination and LIG4-independent end joining in DNA double-strand break repair. *The FEBS journal*.

Kok N, et al. (2025) CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. *iScience*, 28(6), 112548.

Jenkins TW, et al. (2025) Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. *Scientific reports*, 15(1), 17284.

Li J, et al. (2025) Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells. *International immunopharmacology*, 148, 114113.

Song L, et al. (2025) GREM1 deficiency induced bone marrow adipose niche promotes B-cell acute lymphoblastic leukemia disease progression. *International journal of cancer*, 157(3), 559.

Huang Z, et al. (2025) Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e15472.

Adabi E, et al. (2025) Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway. *Cell reports. Medicine*, 6(2), 101970.

Brock L, et al. (2025) KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells. *Molecular oncology*, 19(5), 1404.